Research study Program year 2021 Source: CMS Open Payments

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Subjects with Varying Degrees of Renal Impairment

Research payments

$1,758,864

73 payments

Through program year 2021, $1,758,864 in research payments was reported against A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of BCX9930 in Subjects with Varying Degrees of Renal Impairment, across 73 payments, paid by BioCryst Pharmaceuticals, Inc..

Paid by: BioCryst Pharmaceuticals, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2021	Research	$1,758,864	73

Breakdown

Who paid Research payments · program year 2021

BioCryst Pharmaceuticals, Inc. $1,758,864 73 payments

Who received the money Research payments · program year 2021

Orlando Clinical Research Center Organisation paid for research $441,385 31 payments
National Jewish Health Teaching hospital · CO $437,902 6 payments
Prism Research LLC Organisation paid for research $434,364 18 payments
Alliance For Multispecialty Research LLC Organisation paid for research $293,162 12 payments
University Of Iowa Organisation paid for research $152,052 6 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

4 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.